Literature DB >> 16170812

Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis.

Iván Palomo1, Jaime Pereira, Marcelo Alarcón, Gonzalo Díaz, Patricia Hidalgo, Isabel Pizarro, Eric Jara, Patricio Rojas, Guillermo Quiroga, Rodrigo Moore-Carrasco.   

Abstract

Heparin-induced thrombocytopenia (HIT) type II is a serious complication of heparin therapy. It presents initially as thrombocytopenia, and is associated with thrombosis in 20-50% of the cases. HIT is related to the presence of heparin-induced antibodies (HIA), which show specificity for the PF4-heparin (PF4-H) complex. The FcgammaRIIa receptor has been suggested to participate in the pathogenic mechanism of HIA. Since patients undergoing chronic hemodialysis (HD) are exposed repeatedly to heparin, we studied the prevalence of HIA and their eventual relationship with thrombocytopenia and/or thrombosis, and the possible participation of the FcgammaRIIa polymorphism. We studied 207 patients with chronic renal failure (CRF) undergoing HD. As a control we included 130 blood donors and 28 patients with CRF without HD. The HIA patients were studied with the use of a PF4-H ELISA. Additionally, in some positive cases for the previous test, a 14C- serotonin release assay (14C-SRA) was performed. The polymorphism FcgammaRIIa H/R131 was studied by polymerase chain reaction (PCR) with allele-specific primers. Thirty-seven patients (17.9%) undergoing HD presented with HIA. The majority of these antibodies were IgG, IgM, and IgA. The HIA investigated presented specificity against the PF4-H complex, but not against PF4 alone (P<0.001). Twelve out of 22 (54.5%) PF4-H antibodies were positive when tested with the 14C-SRA. The distribution of the FcgammaRIIa polymorphism in patients and healthy controls was 42.6% and 41.6% for H/H131, 41% and 48.9% for the H/R131 isoform, and 16.4% and 9.5% for the R/R131 isoform, respectively. No statistically significant difference in the FcgammaRIIa isoform distribution was found. Twenty-nine out of 156 patients (18.5%) presented thrombocytopenia, and 21/207 (12.4%) had thrombosis of the native vein arterio-venous fistula (AVF). We did not find any statistically significant between HIA and thrombocytopenia or thrombosis. An important proportion of patients with CRF undergoing HD developed HIA, but these cases were not associated with thrombocytopenia or thrombosis of AVF. The frequency of the FcgammaRIIa polymorphism did not statistically differ between HIT type II and normal controls. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16170812      PMCID: PMC6807933          DOI: 10.1002/jcla.20076

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  33 in total

Review 1.  Polymorphism of the human Fc gamma receptor II (CD32): molecular basis and functional aspects.

Authors:  P A Warmerdam; P W Parren; A Vlug; L A Aarden; J G van de Winkel; P J Capel
Journal:  Immunobiology       Date:  1992-08       Impact factor: 3.144

2.  Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients.

Authors:  T Sitter; M Spannagl; B Banas; H Schiffl
Journal:  Nephron       Date:  1998       Impact factor: 2.847

3.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

Review 4.  The Fc receptor for immunoglobulin G (Fc gamma RII) on human platelets.

Authors:  C L Anderson; G W Chacko; J M Osborne; J T Brandt
Journal:  Semin Thromb Hemost       Date:  1995       Impact factor: 4.180

5.  Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis.

Authors:  G Arepally; S E McKenzie; X M Jiang; M Poncz; D B Cines
Journal:  Blood       Date:  1997-01-15       Impact factor: 22.113

6.  Platelet count, anti-heparin/platelet factor 4 antibodies and tissue factor pathway inhibitor plasma antigen level in chronic dialysis.

Authors:  G Luzzatto; M Bertoli; G Cella; F Fabris; B Zaia; A Girolami
Journal:  Thromb Res       Date:  1998-02-01       Impact factor: 3.944

7.  Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia.

Authors:  J G Kelton; D Sheridan; H Brain; P J Powers; A G Turpie; C J Carter
Journal:  J Lab Clin Med       Date:  1984-04

8.  Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia.

Authors:  G Arepally; C Reynolds; A Tomaski; J Amiral; A Jawad; M Poncz; D B Cines
Journal:  Am J Clin Pathol       Date:  1995-12       Impact factor: 2.493

9.  Single amino acid mutation of Fc gamma receptor is associated with the development of heparin-induced thrombocytopenia.

Authors:  J K Burgess; R Lindeman; C N Chesterman; B H Chong
Journal:  Br J Haematol       Date:  1995-11       Impact factor: 6.998

10.  Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia.

Authors:  J Amiral; M Wolf; A Fischer; C Boyer-Neumann; A Vissac; D Meyer
Journal:  Br J Haematol       Date:  1996-03       Impact factor: 6.998

View more
  11 in total

1.  Screening frequency, incidence and pattern of heparin-induced thrombocytopenia syndrome at a large tertiary institution.

Authors:  Hae Tha Mya; Hui Ming Tay; Shien Wen Gan; Shilpa Surendran; Shu Hui Yeang; Cynthia Ciwei Lim; HuiLin Choong; Lai Heng Lee; Heng Joo Ng
Journal:  Int J Hematol       Date:  2016-04-22       Impact factor: 2.490

2.  Anti-Platelet Factor 4/Heparin Antibody Plays a Significant Role in Progression of Arterial Stiffness among Hemodialysis Patients.

Authors:  Chieh Kuo; Chiang-Chin Tsai; Chien-An Chen; Yueh-Feng Tsai; Yen-Hsun Chen
Journal:  Acta Cardiol Sin       Date:  2017-03       Impact factor: 2.672

3.  Anti-PF4/heparin antibodies are associated with arteriovenous fistula thrombosis in non-diabetic hemodialysis patients.

Authors:  Yueh-Feng Tsai; Chien-An Chen; Chieh Kuo; Kao-Chang Lin
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

Review 4.  [Thrombocytopathy and blood complications in uremia].

Authors:  Walter H Hörl
Journal:  Wien Klin Wochenschr       Date:  2006-04       Impact factor: 1.704

5.  Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes.

Authors:  Vera Krane; Mario Berger; Jürgen Lilienthal; Karl Winkler; Christian Schambeck; Christoph Wanner
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

6.  Anti-platelet factor 4/heparin antibody is associated with progression of peripheral arterial disease in hemodialysis patients.

Authors:  Yen-Hsun Chen; Kao-Chang Lin; Yueh-Feng Tsai; Lai-King Yu; Li-Hsueh Huang; Chien-An Chen
Journal:  Int Urol Nephrol       Date:  2015-07-22       Impact factor: 2.370

7.  Platelet factor 4/heparin antibodies in blood bank donors.

Authors:  Marcie J Hursting; Poulomi J Pai; Julianna E McCracken; Fred Hwang; Shayela Suvarna; Yuliya Lokhnygina; Nicholas Bandarenko; Gowthami M Arepally
Journal:  Am J Clin Pathol       Date:  2010-11       Impact factor: 2.493

8.  Vaccine-induced immune thrombotic thrombocytopenia presenting as a mimic of heparin-induced thrombocytopenia in a hemodialysis patient receiving ChAdOx1 nCoV-19 vaccine.

Authors:  Yi-Ling Lin; Chen-Yuan Lin; Jiung-Hsiun Liu
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 9.  Heparin-induced thrombocytopenia: a renal perspective.

Authors:  Samaha Syed; Robert F Reilly
Journal:  Nat Rev Nephrol       Date:  2009-07-28       Impact factor: 28.314

10.  The clinical significance and risk factors of anti-platelet factor 4/heparin antibody on maintenance hemodialysis patients: a two-year prospective follow-up.

Authors:  Delong Zhao; Xuefeng Sun; Li Yao; Hongli Lin; Jijun Li; Jiuyang Zhao; Zhimin Zhang; Lide Lun; Jianrong Zhang; Mingxu Li; Qi Huang; Yang Yang; Shimin Jiang; Yong Wang; Hanyu Zhu; Xiangmei Chen
Journal:  PLoS One       Date:  2013-04-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.